Clinical Trials Logo

Clinical Trial Summary

Children (Exclusively breast fed: 6mo - 3yrs, and who are not exclusively breast fed 3mo to 3 yrs) with infantile cholestasis syndrome will be randomized to either recieve indigenously prepared oral nutritional supplement (energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician (Group A). The control group (Group B) in comparison will receive standard nutritional counseling from a trained dietician but will not receive any additional nutritional supplement. All the children will be followed up at 1 month, 3 months, 6 months, 9 months and 1 year after inclusion. Clinical, nutritional assessment and laboratory data will be collected at each visit. Additionally IL-6 levels will be done at each visit in children of both arms of the intervention group.

The outcomes of interest will be growth and improvement of nutritional status parameters, hepatic morbidity (ascites, gastrointestinal bleeding, encephalopathy, {SBP (Spontaneous Bacterial Peritonitis), HRS (Hepatorenal Syndrome), etc and outcome (improvement, death or Liver Transplantation}.

All children will receive individualized standard treatment for infantile cholestasis syndrome including vitamin supplements/endotherapy/ beta blockers/ prophylaxis for SBP (Spontaneous Bacterial Peritonitis)/cholangitis (to at risk children) and drug therapy wherever indicated (steroids/ copper chelation/ UDCA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02715973
Study type Interventional
Source Institute of Liver and Biliary Sciences, India
Contact
Status Completed
Phase N/A
Start date January 1, 2016
Completion date October 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT03704792 - Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference N/A
Terminated NCT02949375 - Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease Phase 2
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT00756171 - Colesevelam Versus Placebo in Cholestatic Pruritus Phase 2/Phase 3
Completed NCT01195181 - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Phase 4
Completed NCT05044663 - Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT04802954 - Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients N/A
Recruiting NCT04622449 - Etiopathogenesis of Anemia in Chronic Liver Disease
Enrolling by invitation NCT05836246 - The Development of Quantitative Ultrasound Imaging Software Platform
Completed NCT03087344 - Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis N/A
Completed NCT04751045 - Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies N/A
Not yet recruiting NCT04526548 - A Diagnostic Study on Patients With Drug-induced Liver Injury
Withdrawn NCT02899325 - FDGal PET/CT to Detect Hepatocellular Carcinoma
Suspended NCT02650011 - Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Terminated NCT02530567 - Non-invasive Evaluation of Portal Pressure by MRI N/A
Completed NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy Phase 1
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01600105 - Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) Phase 4
Completed NCT01008293 - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life Phase 2/Phase 3